Chain armor against tumor cells: The oxazole side chain in the antimitotic agent rhizoxin S2 (1) was successfully replaced through mutasynthesis by using an engineered mutant impaired in heterocyclization. Incorporation of 12 non-natural surrogates into fully processed rhizoxin analogues revealed a ...
木桃桃吖 原创视频 38660196,986上次开播前天 23:59 关注 30.0万 客户端看 虎牙直播 386601 正在加载 高清 弹幕 百宝箱 充值 包裹 守护 贵族 公告:🐧2984717996,全平台ID:木桃桃吖 互动守护 近7天暂时无数据 签约公会 正恒传媒 90010本月级别:钻石公会...
Patients were enrolled into two cohorts: the main cohort (HER2-negative MBC patients with gBRCA1/2, gPALB2, gCHEK2) and the exploration cohort (MBC patients with gDDR gene mutations and brain metastases). Simon's Two-Stage design was used for recruiting patients in the main cohort. ...
Also, the microphones may be selectively positioned or pointed to allow the linear cancellation of ambient noise.ERIC DOUGLAS ROMESBURG
To achieve acceptable cost-effectiveness, the cost of first-line osimertinib needs to be reduced by at least 68.4%.doi:10.1080/14737167.2021.1847648Terence KhooLan Gao
LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA studydoi:10.1016/j.annonc.2024.08.2297B. Besse...
In this study, we established a novel leukemic cell line, JMPAL-1, from a specimen of a 69-year-old patient with Philadelphia chromosome-positive MPAL. Flow cytometry showed that JMPAL-1 expresses B-cell markers but not myeloperoxidase. A genomic analysis of JMPAL-1 cells revealed the BCR...
The purpose of this study was to compare the efficacy and safety of the VIC (Vemurafenib/Irinotecan/Cetuximab) regimen versus bevacizumab plus chemotherapy as first-line setting in Asian patients. Methods: In the single-center prospective cohort study, 78 untreated, BRAF V600E-mutant, locally ...
A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carry- ing a p53 point mutation. Leukemia 2000; 14: 922-30.Yagita M, Huang CL, Umehara H et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural ...
A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carry- ing a p53 point mutation. Leukemia 2000; 14: 922-30.Yagita M, Huang CL, Umehara H, Matsuo Y, Tabata R, Miyake M, Konaka Y, Takatsuki K (2000) A novel natural killer cell ...